Spectrum Pharmaceuticals Reports Record Revenues and Profits for First Quarter ... MarketWatch (press release) Conduct the "ZAR" trial, a head-to-head study vs. rituximab maintenance in follicular non-hodgkin's lymphoma in North America Spectrum Pharmaceuticals, a biotechnology company with a primary focus in oncology and hematology, currently markets two ... |
